Identify appropriate patients
for JYNARQUE

Select a patient to see how clinical and imaging markers can indicate the risk of rapid progression
Rapidly declining eGFR
TKV greater than expected for his age
Julia, Patient
Julia, 40
Stage 2 CKD
Multiple risk factors
Cyst-related flank pain
Patient images and patient cases are fictional.

Physical Findings and Labs:

Age:
40
Height:
5’4”
Weight:
177 lbs
BMI:
30

BP: 105/70 mm/Hg, controlled on an ACE-inhibitor

Creatinine: 1.1 mg/dL

eGFR: 77 mL/min/1.73 m2

Ultrasound kidney length: markedly enlarged kidneys, each with a length of >17 cm

Medical history:
  • Diagnosed with ADPKD as a young adult when an ultrasound showed innumerable, bilateral cysts
  • Hyperlipidemia
  • Proteinuria
  • Obesity
  • Hypertension before age 35
Family History:
  • Father had ADPKD, which later progressed to ESKD at age 70

Julia, 40 — Stage 2 CKD

Stage 2 CKD Patient Julia

Julia is a 4th grade teacher who also enjoys painting. She hopes to pass that passion down to her daughters, Charlotte and Nora.

Multiple risk factors and concerning kidney length are signs of risk of rapidly progressing ADPKD.1,7

Assessing ADPKD progression and treatment considerationAssessing ADPKD progression and treatment consideration
  • Julia presented with several risk factors associated with rapid disease progression, including obesity, proteinuria, and hypertension before age 35
  • Because of her young age, her nephrologist decided to request a kidney length measurement via ultrasound5
    • Measuring a patient’s kidney size can help assess the rate of rapid progression before you see eGFR levels decline3
  • Because her kidney length was greater than 17 cm at 40 years of age with CKD Stage 2, Julia’s nephrologist determined that she was at risk for rapidly progressing ADPKD1,7
    • In the CRISP study, a kidney length of >16.5 cm was shown to predict development of CKD Stage 3 within 8 years in patients with ADPKD who were <45 years of age and who had CKD Stage 1 or 29*
  • After further assessment, Julia’s nephrologist determined she was an appropriate patient and recommended she start treatment with JYNARQUE
Starting JYNARQUE
  • Julia has taken her doctor’s advice of exercising more regularly and living a more healthy lifestyle to get her weight under control
  • Julia’s nephrologist explained the benefits and risks associated with treatment, including the risk of serious liver injury, discussed the requirements of the REMS Program, and reviewed the Medication Guide prior to starting treatment
  • Because of her risk factors and concerning kidney length of >17 cm, Julia chose to go on JYNARQUE after her nephrologist explained that it has the ability to slow the progression of ADPKD
    • 48% of the patients in the TEMPO 3:4 clinical trial had CKD Stage 2, like Julia
  • Julia’s nephrologist advised her to take JYNARQUE twice daily, the first dose upon waking and the second dose 8 hours later
    • He explained that JYNARQUE may cause aquaretic side effects and advised to drink more water to avoid thirst and dehydration
  • Because she is a teacher, frequent urination is a concern for Julia. Therefore, the nurse counseled her on ways to help manage aquaretic side effects, including going on a low sodium and protein diet and scheduling bathroom breaks10-12
  • Julia’s nephrologist told her about the Peer Mentor Program. She spoke to a Peer Mentor who shared his experience integrating JYNARQUE into his lifestyle and job, and she felt more comfortable after hearing his JYNARQUE experience
  • Based on Julia’s commercial insurance coverage, her specialty pharmacy determined she was eligible for $10/month copay support†

A CRISP cohort analysis, published in Kidney International, showed that a one-time measurement of TKV can help assess the rate of future kidney function decline.5

ACE=angiotensin-converting enzyme; ADPKD=autosomal dominant polycystic kidney disease; BMI=body mass index; BP=blood pressure; CKD=chronic kidney disease; CRISP=Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease; eGFR=estimated glomerular filtration rate; ESKD=end-stage kidney disease; NIH=National Institutes of Health; REMS=Risk Evaluation and Mitigation Strategy; TEMPO=Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes; TKV=total kidney volume.

*CRISP is an NIH-funded, 14-year observational study (N=241) of adult ADPKD patients. The primary goal was to determine the extent to which TKV forecasts the development of renal insufficiency in ADPKD.5,6

†Assumes one 28-day supply prescription per month. If more than one prescription is filled in a calendar month, patients may pay more than $10 in that month. Other terms and conditions may apply.

Additional resources for you and your patients

ACCESS RESOURCES

  1. Gansevoort RT, Arici M, Benzing T, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant. 2016;31(3):337-348. 
  2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Intern Suppl. 2013;3(1):1-150.
  3. Torres VE, Chapman AB, Devuyst O, et al; for the REPRISE Trial Investigators. Tolvaptan in later-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377(20):1930-1942. 
  4. Irazabal MV, Rangel LJ, Bergstralh EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160-172.
  5. Yu ASL, Shen C, Landsittel DP, et al; for the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP). Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. Kidney Int. 2019;95(5):1253-1261.
  6. Chapman AB, Guay-Woodford LM, Grantham JJ, et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int. 2003;64(3):1035-1045.
  7. Magistroni R, Corsi C, Martí T, Torra R. A review of the imaging techniques for measuring kidney and cyst volume in establishing autosomal dominant polycystic kidney disease progression. Am J Nephrol. 2018;48:67-78. 
  8. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7(3):479-486.
  9. Bhutani H, Smith V, Rahbari-Oskoui F, et al; for the CRISP Investigators. A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int. 2015;88(1):146-151. 
  10. Chebib FT, Perrone RD, Chapman AB, et al. A practical guide for treatment of rapidly progressive ADPKD with tolvaptan. J Am Soc Nephrol. 2018;29(10):2458-2470.
  11. Kramers BJ, van Gastel MDA, Boertien WE, Meijer E, Gansevoort RT. Determinants of urine volume in ADPKD patients using the vasopressin V2 receptor antagonist tolvaptan. Am J Kidney Dis. 2019;73(3):354-362.
  12. Côté G, Asselin-Thompstone L, Mac-Way F, et al. Sodium and urea excretion as determinants of urine output in autosomal dominant polycystic kidney disease patients on V2 receptor antagonists: impact of dietary intervention. Int Urol Nephrol. 2020;52(2):343-349.

INDICATION and IMPORTANT SAFETY INFORMATION

JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).

WARNING: RISK OF SERIOUS LIVER INJURY

WARNING: RISK OF SERIOUS LIVER INJURY

  • JYNARQUE® (tolvaptan) can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported
  • Measure transaminases (ALT, AST) and bilirubin before initiating treatment, at 2 weeks and 4 weeks after initiation, then monthly for the first 18 months and every 3 months thereafter. Prompt action in response to laboratory abnormalities, signs, or symptoms indicative of hepatic injury can mitigate, but not eliminate, the risk of serious hepatotoxicity
  • Because of the risks of serious liver injury, JYNARQUE is available only through a Risk Evaluation and Mitigation Strategy program called the JYNARQUE REMS Program

CONTRAINDICATIONS:

  • History, signs or symptoms of significant liver impairment or injury. This contraindication does not apply to uncomplicated polycystic liver disease
  • Taking strong CYP3A inhibitors
  • With uncorrected abnormal blood sodium concentrations
  • Unable to sense or respond to thirst
  • Hypovolemia
  • Hypersensitivity (e.g., anaphylaxis, rash) to JYNARQUE or any component of the product
  • Uncorrected urinary outflow obstruction
  • Anuria

Serious Liver Injury: JYNARQUE can cause serious and potentially fatal liver injury. Acute liver failure requiring liver transplantation has been reported in the post-marketing ADPKD experience. Discontinuation in response to laboratory abnormalities or signs or symptoms of liver injury (such as fatigue, anorexia, nausea, right upper abdominal discomfort, vomiting, fever, rash, pruritus, icterus, dark urine or jaundice) can reduce the risk of severe hepatotoxicity. To reduce the risk of significant or irreversible liver injury, assess ALT, AST and bilirubin prior to initiating JYNARQUE, at 2 weeks and 4 weeks after initiation, then monthly for 18 months and every 3 months thereafter.

Hypernatremia, Dehydration and Hypovolemia: JYNARQUE therapy increases free water clearance which can lead to dehydration, hypovolemia and hypernatremia. Instruct patients to drink water when thirsty, and throughout the day and night if awake. Monitor for weight loss, tachycardia and hypotension because they may signal dehydration. Ensure abnormalities in sodium concentrations are corrected before initiating therapy. If serum sodium increases above normal or the patient becomes hypovolemic or dehydrated and fluid intake cannot be increased, suspend JYNARQUE until serum sodium, hydration status and volume status parameters are within the normal range.

Inhibitors of CYP3A: Concomitant use of JYNARQUE with drugs that are moderate or strong CYP3A inhibitors (e.g., ketoconazole, itraconazole, lopinavir/ritonavir, indinavir/ritonavir, ritonavir, and conivaptan) increases tolvaptan exposure. Use with strong CYP3A inhibitors is contraindicated; dose reduction of JYNARQUE is recommended for patients taking moderate CYP3A inhibitors. Patients should avoid grapefruit juice beverages while taking JYNARQUE.

Adverse Reactions: Most common observed adverse reactions with JYNARQUE (incidence >10% and at least twice that for placebo) were thirst, polyuria, nocturia, pollakiuria and polydipsia.

Other Drug Interactions:

  • Strong CYP3A Inducers: Co-administration with strong CYP3A inducers reduces exposure to JYNARQUE. Avoid concomitant use of JYNARQUE with strong CYP3A inducers
  • V2-Receptor Agonist: Tolvaptan interferes with the V2-agonist activity of desmopressin (dDAVP). Avoid concomitant use of JYNARQUE with a V2-agonist

Pregnancy and Lactation: Based on animal data, JYNARQUE may cause fetal harm. In general, JYNARQUE should be discontinued during pregnancy. Advise women not to breastfeed during treatment with JYNARQUE.

To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).

Please see FULL PRESCRIBING INFORMATION, including BOXED WARNING.